ONTDEKKENBIBLIOTHEEK
searchclose
shopping_cart_outlined
exit_to_app
category_outlined / Business & Financiën
Dalal Street Investment JournalDalal Street Investment Journal

Dalal Street Investment Journal

Vol.34 No. 4

Thirty one-years old but conventional, Dalal Street Investment Journal (DSIJ), India’s No 1 equity research and capital investment magazine is published every fortnight to cater to the needs of its reader-investors. Armed with a set of chosen experts on markets and corporate India, the fortnightly magazine has its focus on stock market research and recommendations, capital market analysis, personal finance investment advice and also analysis of various economic activities in the country along with its impact on Indian share markets. This is the one and only complete resource guide for a wide loyal base of over 8 lakh HNI readers.

Land:
India
Taal:
English
Uitgever:
DSIJ Pvt Ltd
Meer lezenkeyboard_arrow_down
EDITIE KOPEN
€ 2,66

IN DEZE EDITIE

access_time2 min.
markets cautiously optimistic at the moment!

Market outlook looks cautiously optimistic to me at this point of time with no major worries in sight as of now. We would like to revise our Sensex target from 42,000 to 39,000 level for March 2019. In my view, RBI is playing spoilsport right now and has not done enough to propel economic growth. No business can be done if one is overcautious. RBI has been overcautious for too long in my view. The new RBI governor, I hope, takes a more pragmatic stand on interest rates and support the economy where it matters the most – making finance cheaper for businesses. I expect some interest rate cuts in the coming months. The global economy outlook looks stable with the US and China finally showing signs of trade war dispute…

access_time1 min.
low price

I am new to investing and have been taking guidance from your magazine. Thank you for making life easy for new investors such as me. Can you tell me more about your Low Price recommendations in the magazine. Chetan Tupe Editor Responds: Thank you for your kind words. The Low Price Scrips are well-researched stock investment ideas hand-picked by our research team. The stocks are fundamentally sound and have the potential to deliver double digit returns in less than one year. We highly recommend investing in all the Low Price Scrips that are featured in the magazine. A specific amount of capital can be parked in each Low Price Scrip recommendation for optimal returns. Hope this helps you in using our magazine recommendations profitably. Recommendations facebook.com/DSIJin enquiry@dsij.in www.dsij.in/apps.aspx twitter.com/DSIJ linkedin.com/in/DalalStreetInvestmentJournal…

access_time2 min.
markets looking forward to earnings for triggers

As anticipated, the markets witnessed a tepid start to the New Year 2019. Global cues put down any excitement that tried to initiate a rally both ways during the fortnight. On the upside, the BSE Sensex tested 36,254, while on the downside, it dipped to 35,513. Markets have started reacting to earnings reports and outlook given by India Inc, with a consensus view that earnings will pick up, thereby giving direction to the indices. The first fortnight of 2019 saw BSE Sensex and Nifty50 posting losses of 0.16 and 0.62 percent, respectively. The broader indices followed the same trend with the BSE Mid-cap and Small-cap losing 1.69 and 0.72 percent, respectively, during the fortnight. Sectorally, BSE Metal and Auto index lost the most as most automobile makers registered a drop in…

access_time2 min.
reap the benefits of diversification with itc

HERE IS WHY Differentiated product development capacity Robust portfolio of brands Efficient marketing and distribution network ITC is a conglomerate boasting a vibrant portfolio of businesses encompassing FMCGs, hotels, paperboards and specialty papers, packaging, agri-business and IT. On the standalone quarterly front, total income from operations rose to ₹11,272.51 crore in Q2FY19 as against ₹9,763.92 crore in Q2FY18, thereby rising 15.45 percent. EBITDA reached ₹4,205.97 crore in Q2FY19 in comparison to ₹3,211.3 crore in Q2FY18, posting a growth of 30.97 percent. Net profit climbed to ₹2,954.67 crore in Q2FY19 from ₹2,639.84 crore in Q1FY18, registering an increase of 11.92 percent. Basic EPS rose to ₹2.42 in Q2FY19 from ₹2.17 in Q2FY18. On the consolidated annual front, total income from operations soared to ₹43,448.94 crore in FY18 versus ₹42,803.61 crore in FY17, thereby rising 1.50 percent. EBITDA…

access_time3 min.
power-packed performance!

HERE IS WHY Strong bottom-line Attractive valuations Company enjoys competitive edge BC Power Controls (BCPCL) manufactures and trades in copper wires and cables. The company manufactures ferrous and non-ferrous metal items which comprises of wires and cables and handcrafts. It is engaged in manufacturing insulated wires and cables, copper and copper products, and aluminium products. Its products include flexible cables, armoured cables, telephone cables, unarmoured cables, submersible cables, instrumentation cables and shielded cables. Its product portfolio includes armoured and unarmoured cables, etc. It derives 70% of revenue from manufacturing cables and the rest from trading. The company achieved an all-time high performance both in turnover and profits. The sector has witnessed a surge in demand for cables and wires and most of the players in the sector have benefited from the rising demand. BC Power…

access_time2 min.
hot chips 15 days investment horizon

STRIDES PHARMA SCIENCE Strides Pharma Science Ltd. develops and manufactures IP-led niche finished dosage formulations and is one of the world’s largest manufacturers of soft gelatin capsules. The company reported a consolidated net loss of ₹8.70 crore in Q2FY19 as against net profit of ₹11.73 crore in Q2FY18. With 26 ANDAs pending approval and addressable opportunities worth US$ 9.7 billion, the company has a robust approval momentum with eight approvals already received in FY19. The company entered into a strategic partnership with SUDA Pharmaceuticals on November 9, 2018, for an oral spray for the US market. In Q2FY19, it received acceptance for two key ANDAs under the newly introduced competitive generic therapy with a combined market of US$ 550 million. Its chief growth drivers are expansion in product portfolio and geographical…

help